The US FDA’s risk evaluation mitigation strategy (REMS) can be a challenge for pharmaceutical companies unfamiliar with the process according to PPD’s executive director of risk management Frank Gallo.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
